Amarin Corporation plc announced the launch of True To Your Heart, an educational campaign to help people learn more about cardiovascular disease and how to better protect against persistent cardiovascular risk.
First-time marathon runners can add years to their lives and reap the health rewards of lower blood pressure and healthier arteries, even if they take on the challenge in mid-to-later life, research showed.
Sanofi is ending diabetes and cardiovascular (DCV) research efforts as part of a revamp to narrow the number of the company’s business units in the hope of bolstering growth and profit.
Amgen filed a Worker Adjustment and Retraining in California with plans to cut 172 jobs at the company’s headquarters and U.S. field operations effective December 31, 2019.
A panel of experts to the U.S. FDA recommended allowing Amarin Corp. Plc’s fish-oil derived drug to be used as an add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease.
Bayer and biotechnology company Dewpoint Therapeutics announced an option, research and license agreement worth up to $100 million.
The U.S. FDA approved Janssen’s Xarelto (rivaroxaban) for preventing blood clots in acutely sick patients in hospitals who are at risk for blood clots but who are not at high risk of bleeding.
Few nutritional supplements can protect people from developing or dying from cardiovascular disease, and some may actually be harmful, a research review suggests.
Obese people who engaged in resistance training were more likely to see reductions in a type of heart fat, a new study finds.
The U.S. FDA approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism in pediatric patients 1 month of age and older.
